#United States #Washington #Vanda Pharmaceuticals #Tradipitant #NEREUS™

Vanda Pharmaceuticals Introduces NEREUS™

In an exciting development for millions of Americans, Vanda Pharmaceuticals Inc. has announced the commercial availability of NEREUS™ (tradipitant), the first new pharmacologic treatment for motion sickness in over four decades. This innovative medication can now be ordered directly by consumers through the dedicated website nereus.us.

Motion sickness affects a significant number of people, with estimates suggesting that between 65 to 78 million Americans, or 25 to 30 percent of adults, experience symptoms during common travel occasions, whether by car, plane, or boat. Until now, those suffering from this condition had little to no meaningful treatment options; however, NEREUS™ presents a promising solution.

What is NEREUS™?

NEREUS™ acts as a selective neurokinin-1 (NK-1) receptor antagonist, specifically designed to prevent vomiting induced by motion. This mechanism targets the vomiting center of the brain, offering a modern and effective approach to tackling a problem that has seen little innovation in pharmacology for a long time. In a statement, Dr. Mihael H. Polymeropoulos, President and CEO of Vanda, emphasized, "Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel."

Due to its novel mechanism of action, NEREUS™ is expected to provide effective relief for many, hoping to change the travel experience for those affected.

The Launch and Availability

As of May 4, 2026, NEREUS™ is available across retail pharmacies nationwide and can also be purchased through the direct-to-consumer platform at nereus.us. For individuals with a valid prescription, NEREUS™ can now be obtained at a cash-pay price of $85 per dose, significantly lower than the standard list price of $255.

Motion Sickness: A Hidden Challenge

Historically, motion sickness has not only hindered personal travel but has also affected military effectiveness and exploration. Events from Napoleon's 1798 campaign to modern space travel highlight the widespread impact of this condition. Research demonstrates that motion sickness arises when there is a sensory mismatch between signals received from the eyes, inner ear, and body. This disruption can lead the brain to release a neuromodulator known as substance P, which triggers nausea and vomiting.

NEREUS™ intervenes at this critical juncture by blocking NK-1 receptors, disrupting the pathway that leads to vomiting during motion. This component of the drug approach is groundbreaking, as it marks the first new prescription option in over 40 years, targeting a long-standing medical challenge.

Clinical Trials and FDA Approval

The journey towards bringing NEREUS™ to the market involved rigorous testing, culminating in FDA approval on December 30, 2025. Two significant Phase 3 clinical trials, Motion Syros and Motion Serifos, provided compelling evidence of its efficacy in preventing vomiting compared to a placebo in real-world conditions, particularly at sea.

Patients taking NEREUS™ administer just one or two capsules about an hour before travel, which simplifies the treatment regimen, making it more accessible to those frequently affected by motion sickness.

Importance of Accessibility and Education

The commercial launch of NEREUS™ signifies a historic milestone in addressing motion sickness, a condition that has plagued humans for centuries. Moreover, Vanda's commitment to providing this treatment through both established pharmacy channels and an online platform emphasizes its dedication to accessibility and patient choice. For more information on how to access NEREUS™, visit nereus.us.

Conclusion

As Vanda Pharmaceuticals steps into the forefront with the launch of NEREUS™, it paves the way for new possibilities in treating motion sickness. With a focus on innovation and accessibility, the medicine not only aims to improve the lives of millions but also represents a significant advancement in the pharmaceutical industry. Individuals suffering from motion sickness can finally find relief and reclaim their travel experiences without the fear of nausea disrupting their journeys. The launch of NEREUS™ promises a brighter future for those grappling with motion sickness across the nation.